Royalty Pharma plc - Ordinary Shares - Class A Forecast, price target & analysts
Royalty Pharma plc - Ordinary Shares - Class A Target price 2026 - Analyst rating & recommendation
Royalty Pharma plc - Ordinary Shares - Class A Classifications & Recommendation
Royalty Pharma plc - Ordinary Shares - Class A Price Target
| Target Price | $66.81 |
| Price | $57.16 |
| Potential |
16.88%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Royalty Pharma plc - Ordinary Shares - Class A 2027 .
The average Royalty Pharma plc - Ordinary Shares - Class A target price is $66.81.
This is
16.88%
register free of charge
$73.50
28.59%
register free of charge
$46.46
18.72%
register free of charge
|
|
| A rating was issued by 16 analysts: 14 Analysts recommend Royalty Pharma plc - Ordinary Shares - Class A to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Royalty Pharma plc - Ordinary Shares - Class A stock has an average upside potential 2027 of
16.88%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.38 | 3.40 |
| 5.06% | 43.13% | |
| Net Margin | 32.42% | 92.46% |
| 14.57% | 185.22% |
12 Analysts have issued a sales forecast Royalty Pharma plc - Ordinary Shares - Class A 2026 . The average Royalty Pharma plc - Ordinary Shares - Class A sales estimate is
This results in the following potential growth metrics:
12 Royalty Pharma plc - Ordinary Shares - Class A Analysts have issued a net profit forecast 2026. The average Royalty Pharma plc - Ordinary Shares - Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.36 | 5.47 |
| 5.56% | 302.21% | |
| P/E | 10.45 | |
| EV/Sales | 12.04 |
12 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast for earnings per share. The average Royalty Pharma plc - Ordinary Shares - Class A EPS is
This results in the following potential growth metrics and future valuations:
Royalty Pharma plc - Ordinary Shares - Class A...
Current Royalty Pharma plc - Ordinary Shares - Class A Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| TD Cowen |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | May 07 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | May 07 2026 |
| UBS |
Locked
➜
Locked
|
Locked | Apr 21 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Apr 10 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
TD Cowen:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
May 07 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
May 07 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
Apr 21 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Apr 10 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
